Company Overview and News

 
BSE to move 8 companies out of surveillance framework from Sep 24

2018-09-23 moneycontrol
Leading exchange BSE will move out eight companies from the additional surveillance measure (ASM) framework from September 24. The companies are Commex Technology, Oscar Investments, Tiaan Ayurvedic & Herbs, ACI Infocom, Kretto Syscon, Oasis Tradelink, Usher Agro, and VKJ Infradevelopers.
COMMEXTECH ACIIN 517356 532765 538547 536128 533104 USHERAGRO 532342 VKJINFRA OSCAR 501179 OASIS GLOBUSSPR

 
BSE to move 8 cos out of ASM framework from Sept 24

2018-09-23 thehindubusinessline
The BSE will move out eight companies from the additional surveillance measure (ASM) framework from September 24. The companies are Commex Technology, Oscar Investments, Tiaan Ayurvedic & Herbs, ACI Infocom, Kretto Syscon, Oasis Tradelink, Usher Agro, and VKJ Infradevelopers.
COMMEXTECH ACIIN 517356 532765 538547 536128 533104 USHERAGRO 532342 VKJINFRA OSCAR 501179 OASIS GLOBUSSPR

 
Twist in tale: Religare Enterprises moves NCLT to recover siphoned funds from Singh Brothers

2018-09-14 moneycontrol
In a new and significant twist to the ongoing Singh brothers saga, Religare Enterprises has moved to the National Company Law Tribunal (NCLT) to recover funds siphoned off from the company held by the two siblings.
FORTIS OSCAR 532915 RELIGARE 501179 532843

 
HC asks Malvinder to deposit Rs 18.21 cr after order violation

2018-09-06 freepressjournal.in
New Delhi : The Delhi High Court on Wednesday directed former Ranbaxy Laboratories promoter Malvinder Singh to deposit with it S$3.5 million (around Rs 18.21 crore), which he obtained by selling his shares in a company in violation of court’s direction.
FORTIS OSCAR 532915 RELIGARE 501179 532843

 
Shivinder Singh says brother Malvinder forged wife#39;s signature

2018-09-05 moneycontrol
Former Fortis Healthcare promoter Shivinder Mohan Singh has alleged that his elder brother Malvinder forged his wife's signature, perpetrated illegal financial transactions and led the company into an unsustainable debt trap.
FORTIS OSCAR 532915 RELIGARE 501179 532843

 
Ex-Ranbaxy promoter in disobedience of HC order, directed to deposit 3.5 million Singapore dollars

2018-09-05 moneycontrol
The Delhi High Court Wednesday directed former Ranbaxy Laboratories Ltd promoter Malvinder Singh to deposit with it 3.5 million Singapore dollars, which he obtained by selling his shares in a company in violation of court's direction.
AXBKY YESBANK AXBA AXB AXISBANK OSCAR 501179 532648 YYBKY 532215

 
Delhi HC tells Malvinder Singh to deposit 3.5 million Singapore dollars

2018-09-05 livemint
New Delhi: The Delhi High Court on Wednesday directed former Ranbaxy Laboratories Ltd promoter Malvinder Singh to deposit with it 3.5 million Singapore dollars, which he obtained by selling his shares in a company in violation of the court’s direction.
AXBKY YESBANK AXBA FORTIS AXB AXISBANK OSCAR 501179 532648 YYBKY 532843 532215

 
Daiichi-Ranbaxy row: Delhi HC restrains Singh brothers from using bank a/cs

2018-08-11 livemint
New Delhi: The Delhi high court on Friday restrained former Ranbaxy Laboratories Ltd promoters Malvinder and Shivinder Singh from operating their bank accounts in India or abroad and selling any property.
OSCAR 501179

13
Daiichi case: Delhi HC allows sale of Malvinder Singh’s shares

2018-05-14 livemint
New Delhi: The Delhi high court on Monday ordered the sale of unencumbered listed shares owned by former Ranbaxy promoter Malvinder Singh and others, in connection with the recovery of a Rs3,500 crore arbitration award in favour of Japanese drugmaker Daiichi Sankyo Co. Ltd.
AXBKY YESBANK AXBA FORTIS AXB AXISBANK OSCAR 501179 532648 YYBKY 532843 532215

3
Daiichi Sankyo case: Delhi HC orders sale of Shivinder Singh’s unencumbered listed shares

2018-05-08 livemint
New Delhi: The Delhi high court on Tuesday ordered the sale of unencumbered listed shares owned by former Ranbaxy promoter Shivinder Singh and others in connection with the recovery of a Rs3,500 crore arbitration award in favour of Japanese drugmaker Daiichi Sankyo Co. Ltd.
YESBANK OSCAR 501179 532648 YYBKY

1
Ranbaxy case: Delhi HC seeks details of exchange-listed shares held by Singh brothers

2018-04-25 livemint - 1
New Delhi: The Delhi high court on Wednesday asked a court-appointed chartered accountant to submit a list of all exchange-listed unpledged shares held by former Ranbaxy promoters Malvinder Mohan Singh and Shivinder Mohan Singh and others in relation to the enforcement of a Rs3,500 crore arbitration case with Japanese drug maker Daiichi Sankyo Co. Ltd.
FORTIS OSCAR 501179 532843

1
HC asks Fortis’ reply in Daiichi Sankyo’s attempt to stop its sale to Manipal

2018-04-06 livemint - 1
New Delhi: The Delhi high court on Thursday directed Fortis Healthcare Ltd to file its reply and affidavit in an application moved by Japanese drugmaker Daiichi Sankyo seeking to prevent the sale of Fortis Healthcare to Manipal Health Enterprises.
FORTIS OSCAR 501179 532843

 
Fortis Healthcare rises 5%; Delhi Court asks firm to respond on Daiichi#39;s plea to stall restructuring process

2018-04-06 moneycontrol
Fortis Healthcare share price gained more than 5 percent intraday Friday after the Delhi Court asked company to respond on Daiichi's plea to stall restructuring process.
FORTIS OSCAR 501179 532843

 
Delhi HC orders attachment of Singh brothers’ moveable assets

2018-03-23 livemint
New Delhi: The Delhi high court on Friday ordered the attachment of all moveable property disclosed in an affidavit by former Ranbaxy Laboratories promoters, brothers Malvinder Singh and Shivinder Singh, and others in relation to a Rs3,500 crore arbitration case with Japanese drug maker Daiichi Sankyo Co. Ltd.
OSCAR 501179

 
Daiichi arbitration case: Delhi High Court orders attachment of Singh brothers#39; declared assets

2018-03-23 moneycontrol
The Delhi High Court on Friday ordered attachment of all declared assets of Singh brothers in a case related to the enforcement of a foreign arbitration award of Rs 3,500 crore by Japanese drug maker Daiichi Sankyo, according to a CNBC-TV18 report.
OSCAR 501179

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...